Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 4NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 25Neoplasms 9Kidney Neoplasms 8Prostatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Colorectal Neoplasms 4Carcinoma, Medullary 4Carcinoma 4Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Pain 2Ovarian Neoplasms 2Liver Neoplasms 2von Hippel-Lindau Disease 1Urologic Neoplasms 1Thyroid cancer, follicular 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Kidney Diseases 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1

Interventions

Sunitinib 4Ipilimumab 3pazopanib 2fludarabine 2Nivolumab 2cabozantinib 1atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1LY2510924 1Cyclophosphamide 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Clear-cell metastatic renal cell carcinoma × cabozantinib × Clear all
NCT07011719 2026-06-02

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Arcus Biosciences, Inc.

Phase 3 Recruiting
720 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡